{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.00","upperLimit":"43.00","value":"23.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Time to complete response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) was ≤ 10.8 mg/dL (2.7 mmol/L). Participants were censored on the last CSC assessment day if no complete response was observed. If there was no post-baseline CSC assessment, time to complete response was censored on study Day 1. Time to complete response was analyzed using Kaplan-Meier methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15.","id":"OG000","title":"Denosumab"}],"paramType":"MEDIAN","populationDescription":"Response Analysis Subset","reportingStatus":"POSTED","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.","title":"Time to Complete Response","type":"SECONDARY","unitOfMeasure":"days"}